Moreover, the 36-month beta value for ALGS is 2.69. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALGS is 4.22M and currently, short sellers hold a 13.10% of that float. On June 20, 2025, ALGS’s average trading volume was 157.79K shares.
ALGS) stock’s latest price update
The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) has surged by 11.16 when compared to previous closing price of 7.53, but the company has seen a 6.08% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately.
ALGS’s Market Performance
Aligos Therapeutics Inc (ALGS) has seen a 6.08% rise in stock performance for the week, with a 42.11% gain in the past month and a -28.77% plunge in the past quarter. The volatility ratio for the week is 7.90%, and the volatility levels for the past 30 days are at 6.71% for ALGS. The simple moving average for the last 20 days is 26.80% for ALGS stock, with a simple moving average of -46.32% for the last 200 days.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with H.C. Wainwright repeating the rating for ALGS by listing it as a “Buy.” The predicted price for ALGS in the upcoming period, according to H.C. Wainwright is $75 based on the research report published on August 19, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2. The rating they have provided for ALGS stocks is “Overweight” according to the report published on January 06th, 2023.
Jefferies gave a rating of “Buy” to ALGS, setting the target price at $3 in the report published on January 06th of the previous year.
ALGS Trading at 45.98% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.12% of loss for the given period.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -26.41 for the present operating margin
- 0.61 for the gross margin
The net margin for Aligos Therapeutics Inc stands at -16.29. The total capital return value is set at -0.66. Equity return is now at value -60.44, with -38.23 for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -10.02.
Currently, EBITDA for the company is -89.15 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of -4.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.56.
Conclusion
To wrap up, the performance of Aligos Therapeutics Inc (ALGS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
